[Acute coronary syndrome: present and future]
Alexandre Berger1, Eric Eeckhout
1Service de Cardiologie, CHUV BH-16, Lausanne. alexandre.berger@hospvd.ch
Insights
Acute coronary syndromes (ACS) research focuses on new biological markers and treatments. Early invasive strategies are confirmed, with new anticoagulants and stem-cell therapy showing promise for managing cardiac injuries.
Area of Science:
- Cardiology
- Biomedical Research
Context:
- Acute coronary syndromes (ACS), encompassing ST-elevation myocardial infarction and unstable angina/non-Q wave myocardial infarction, represent a significant area of ongoing medical research.
- Current research explores novel biological markers such as BNP, myeloperoxidase, and CD401 for detecting cardiac injuries.
Purpose:
- To review current research and future directions in the management of acute coronary syndromes.
- To highlight advancements in diagnostic tools, therapeutic strategies, and adjuvant treatments for ACS.
Summary:
- The early invasive strategy remains the cornerstone of ACS management.
- Investigational technological devices, including intracoronary thermotools, are under evaluation.
- New therapeutic avenues include the oral anticoagulant ximelagatran and stem-cell transplantation post-myocardial infarction, with initial human studies demonstrating positive outcomes.
Impact:
- This research provides a comprehensive overview of the evolving landscape of ACS management.
- Findings support the integration of novel biomarkers and advanced therapeutic strategies into clinical practice.
- Future directions emphasize personalized treatment approaches and regenerative medicine for improved patient outcomes in ACS.
Abstract:
The management of the acute coronary syndromes (ACS), made of the acute myocardial infarction (ACS with ST-segment elevation) and the unstable angina/non-Q wave myocardial infarction (ACS without ST-segment elevation), are a major source of research. BNP, myeloperaxidase or CD401 as biological markers of cardiac injuries and technological devices (intracoronary thermotools under investigations. On the therapeutic point of view, the early invasive strategy is confirmed. Therefore, the optimalization of the adjuvant treatment was broadly investigated. Ximelagatran, a new oral anticoagulant, should find a place in the management of our unstable patient based on recent studies. Finally, stem-cell transplantation after myocardial infarction will be probably a new treatment strategy. The first human study is just finished, demonstrating the benefit of this approach. The acute coronary syndromes are a major source of research based on the proof of today and on the wishes for tomorrow.
More Related Videos
05:41Left Anterior Descending Coronary Artery Ligation for Ischemia-Reperfusion Research: Model Improvement via Technical Modifications and Quality Control
Published on: December 16, 2022
05:58Testing Acetylcholine Followed by Adenosine for Invasive Diagnosis of Coronary Vasomotor Disorders
Published on: February 3, 2021
Related Concept Videos
Acute Coronary Syndrome II: Pathophysiology and Clinical Manifestations
Acute Coronary Syndrome III: Diagnostic Studies
Acute Coronary Syndrome IV: Interprofessional Care
Acute Coronary Syndrome I: Introduction
Acute Coronary Syndrome V: Nursing Management
Coronary Artery Disease III: Clinical Manifestations
